The anticoagulants market

Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant

“…The use of dabigatran as an alternative to warfarin received a class I recommendation from the American College of Cardiology and the American Heart Association in February 2011 [1]. The United States anticoagulant market is expected to grow to over US $9 billion in 2014 from US $6 billion in 2008; direct thrombin inhibitors and factor Xa inhibitors combined will comprise over half this market [2].…”

Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays

“…Anticoagulants including unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) are commonly administered to patients for the treatment of cardiovascular diseases such as arterial thromboembolism and coronary artery disease [1][2][3]. While UFH can be monitored using conventional clot-based says such as the activated partial thromboplastin time (APTT) and activated clotting time (ACT), these tests cannot be used to accurately determine LMWH activity [3][4][5][6].…”

Unmet need and limitations of current anticoagulation therapy for stroke prevention in atrial fibrillation patients: a questionnaire based study

“…This was followed by the approval of rivaroxaban and apixaban for this indication. 11 Newer oral direct thrombin inhibitor like, dabigatran etexilate (dabigatran), was shown to be effective as an anticoagulant in the treatment of patients with atrial fibrillation in the randomized evaluation of long-term anticoagulation therapy (RE-LY) study. 12,13 In another large trial dabigatran etexilate 150 mg twice daily has yielded superior results to warfarin for prevention of embolism and stroke in patients of atrial fibrillation.…”

“…The prescription of dabigatran may have been based on the results of the RE-LY trial. 11,15 Some other study done by Moser M et al mentioned that prohibitively high cost of newer oral anticoagulation (NOAC) drugs resulting in poor compliance of patients. 25 We found that all cardiologists think that newer oral anticoagulation therapy without antidote can be accepted over warfarin, if they are safe enough.…”